Table 1.
Correlation of HDLBP Expression With Clinicopathological Parameters From Patient Cohort 2 in This Study
| HDLBP | High (n = 57) | Low (n = 70) | P-value | |
|---|---|---|---|---|
| BCLC stage | A | 17 | 32 | < .018a |
| B | 20 | 28 | ||
| C | 20 | 10 | ||
| Lymph node metastasis | No | 39 | 45 | .601 |
| Yes | 17 | 24 | ||
| Tumor differentiation | Poor | 55 | 27 | < .001a |
| Well | 1 | 28 | ||
| Liver cirrhosis | No | 19 | 23 | 1.000 |
| Yes | 38 | 46 | ||
| Number of HCC | 1 | 41 | 59 | .087 |
| >1 | 15 | 10 | ||
| HBsAg | − | 11 | 17 | .500 |
| + | 46 | 53 | ||
| HBV DNA | − | 32 | 45 | .350 |
| + | 25 | 25 | ||
| Child-Pugh classification | A | 56 | 65 | .155 |
| B | 1 | 5 | ||
| Microsatellite nodules | No | 36 | 57 | .004a |
| Yes | 20 | 9 | ||
| Sorafenib efficacy | PD + SD | 56 | 17 | < .001a |
| PR + SR | 1 | 53 | ||
| Maximum tumor diameter, cm | 8.388 ± 3.292 | 4.839 ± 2.400 | .005a | |
| Total tumor diameter, cm | 6.653 ± 3.714 | 5.236 ± 2.420 | .022a | |
| HGB, g/L | 148.900 ± 14.483 | 145.800 ± 19.587 | .328 | |
| TBIL, μmol/L | 17.120 ± 7.274 | 17.170 ± 10.734 | .978 | |
| DBIL, μmol/L | 6.761 ± 4.014 | 5.996 ± 2.681 | .204 | |
| ALT, IU/L | 70.880 ± 118.273 | 78.790 ± 103.570 | .694 | |
| AST, IU/L | 75.910 ± 127.287 | 76.210 ± 114.382 | .989 | |
| ALB, g/L | 43.260 ± 5.450 | 42.510 ± 5.475 | .448 | |
| UREA, mmol/L | 4.895 ± 1.428 | 5.188 ± 1.440 | .258 | |
| CREA, μmol/L | 73.900 ± 12.654 | 75.240 ± 19.617 | .659 | |
| PT, s | 20.170 ± 1.915 | 20.300 ± 1.525 | .665 | |
| INR | 1.265 ± 1.451 | 1.060 ± 0.135 | .241 | |
| Meld score | 8.201 ± 3.862 | 7.834 ± 2.078 | .496 | |
Note: Data are presented as number or mean ± standard deviation.
ALB, Albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BCLC, Barcelona Clinic Liver Cancer; CR, complete remission; CREA, creatinine; DBIL, direct bilirubin; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HDLBP, high-density lipoprotein binding protein;; HGB, hemoglobin; High, High expression; INR, international normalized ratio; Low, Low expression; Meld, model end-stage liver disease; PD, progressive disease; PR, partial remission; PT, prothrombin time; SD, stable disease; TBIL, total bilirubin.
Indicates statistical significance.